Curis (CRIS) Depreciation & Amortization (CF) (2010 - 2026)
Curis' (CRIS) quarterly Depreciation & Amortization (CF) came in at $8000.0 in Q1 2026, down 86.44% YoY from $59000.0 in Q1 2025, and down 88.06% on a QoQ basis from $67000.0 in Q4 2025.
Curis (CRIS) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Curis (CRIS) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $8000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 86.44% year-over-year to $8000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $149000.0 (down 23.59% YoY) and the FY2025 annual result came in at $200000.0, changed 0.0% from the prior year.
- Depreciation & Amortization (CF) eased to $8000.0 in Q1 2026, from $67000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $109000.0 in Q4 2023 to a low of $8000.0 in Q1 2026.
- A 5-year average of $55352.9 and a median of $61000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) tumbled 88.07% — and 2025, when it soared 415.38%.
- Tracing CRIS's Depreciation & Amortization (CF) over 5 years: stood at $92000.0 in 2022, then grew by 18.48% to $109000.0 in 2023, then plunged by 88.07% to $13000.0 in 2024, then soared by 415.38% to $67000.0 in 2025, then tumbled by 88.06% to $8000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $8000.0 (Q1 2026), $67000.0 (Q4 2025), and $32000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Curis | 3.27 Mn | -2.35 Mn | - | 8,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8,000.00 |
| Mar 31, 2026 | 8,000.00 |
| Dec 31, 2025 | 67,000.00 |
| Dec 31, 2025 | 67,000.00 |
| Sep 30, 2025 | 32,000.00 |
| Sep 30, 2025 | 32,000.00 |
| Jun 30, 2025 | 42,000.00 |
| Jun 30, 2025 | 42,000.00 |
| Mar 31, 2025 | 59,000.00 |
| Mar 31, 2025 | 59,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Jun 30, 2024 | 62,000.00 |
| Jun 30, 2024 | 62,000.00 |
| Mar 31, 2024 | 64,000.00 |
| Mar 31, 2024 | 64,000.00 |
| Dec 31, 2023 | 109,000.00 |
| Dec 31, 2023 | 109,000.00 |